cross tolerance & cross dependency
DESCRIPTION
TRANSCRIPT
![Page 1: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/1.jpg)
Cross Tolerance & Cross Dependency Between Opioids & Cannabinoids
in isolated tissues in cholestasis model
By M.H.Farjoo
Neuroscience research center & pharmacology Dep.Shahid Beheshti University Of Medical Science
![Page 2: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/2.jpg)
Abbreviations
• GPI = Guinea pig ileum • MVD = Mouse vas deferens• ACEA = Arachidonyl chloroethylamide
(cannabinoid agonist)
![Page 3: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/3.jpg)
Contents
Why this topic ?
Goals
Tolerance
Dependency
Cross tolerance and cross dependency
Methods & material
Results for tolerance
Results for dependency
Discussion & conclusion
Acknowledgements
![Page 4: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/4.jpg)
Why this topic ?
• It was feasible in Iran!!• Drug abuse is a major
problem in our country• Possible applications for
drug abuse is worth the cost and time
• Cholestasis is a common problem in Iran.
• Cholestasis is a quite valid model for research on opioids and it is a well characterized model in our research centers.
• Cannabinoids are under intensive research all over the world.
![Page 5: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/5.jpg)
Goals
• Evaluation of occurrence of tolerance and/or dependency to cannabinoid and/or opioid in GPI and/or MVD in sham/cholestatic group
• Evaluation of occurrence of cross tolerance and/or cross dependency between cannabinoid and opioid (and vice versa) in GPI and/or MVD in sham/cholestatic group
![Page 6: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/6.jpg)
Definition of Tolerance
• Reduction in sensitivity to an agent following repeated exposure
• Decrease in agonist effect during a time course and/or significant shift to right of Dose-Response curve
![Page 7: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/7.jpg)
![Page 8: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/8.jpg)
Classification of Tolerance
• Homologous : Specific to the agonists of the same system– Within seconds to minutes (Desensitization) un-coupling of R
and G-protein (with or without internalization) , high dose of agonist
– Within hours : alteration in AC
• Heterologous : Extends to agonists of other systems– Within days, down regulation of sodium pump & partial
depolarization , gene modulation
![Page 9: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/9.jpg)
Mechanism of Tolerance
• Not well understood• VERY complex • Contradictory data!!• Best studied in opioids and cannabinoids
(GPCRs)• Mechanisms of tolerance to any agent can be
absolutely specific!!
![Page 10: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/10.jpg)
Dependency
• Definition:– Absolute requirement for the agent to maintain
normal physiological function
• Classification:– Physical: presence of withdrawal reactions– Psychic: presence of a “drug craving” component
![Page 11: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/11.jpg)
Cross Tolerance
• Definition– Tolerance to an exposed agonist elicits tolerance to other
NON exposed agonists
• Classification– Within agonists of one system (or subtype receptors of one
system)– Between agonists of two (or more) system
![Page 12: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/12.jpg)
Cross Dependency
• Definition– Withdrawal syndrome elicited by antagonist of an
exposed agent can also be precipitated by antagonists of NON exposed agents
• Classification– Within antagonists of one system– Between antagonists of two (or more) system
![Page 13: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/13.jpg)
Mechanism
Exact mechanism of cross tolerance & cross dependency is:
UNKNOWN !
![Page 14: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/14.jpg)
Methods and Materials
![Page 15: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/15.jpg)
Drugs & Animals
• Morphine (temad)• Naloxone• ACEA (sigma)• AM 251 (sigma)• phenylephrine
• Male mice (pasteur and razi institute)
• Male Guinea pig (pasteur institute)
![Page 16: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/16.jpg)
Method for tolerance
1. Animal euthanized by least possible pain
2. Target tissue isolated and prepared
3. Isolated tissue was suspended and stretched in organ bath (with/without drug) for adaptation
4. Tissue stimulated by electrical impulses
5. Result of stimulation registered and analyzed
![Page 17: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/17.jpg)
Method for dependency
1. Animal euthanized by least possible pain2. Target tissue isolated and prepared3. Isolated tissue was suspended and stretched in organ
bath with drug for adaptation and tolerance development
4. Tissue stimulated by relevant agonist (phenylephrine for MVD & acetyl choline for GPI) to elucidate maximal response
5. Relevant antagonist is added and response measured6. Degree of dependency (tension ratio) is calculated
![Page 18: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/18.jpg)
Results(for tolerance)
![Page 19: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/19.jpg)
IC50 of morphine in Intact MVD(n = 6-8)
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
110%
0.E+00 1.E-09 3.E-09 1.E-08 3.E-08 1.E-07 3.E-07 1.E-06 3.E-06
Molarity of drug
perc
ent
of in
hibi
tion
IC50=1.62 E-07
![Page 20: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/20.jpg)
IC50 of morphine in Intact MVD after incubation with 0.5 IC50 for 2 hr (n = 6-8)
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
110%
0.E+00 1.E-09 3.E-09 1.E-08 3.E-08 1.E-07 3.E-07 1.E-06 3.E-06
Molarity of drug
prec
ent
of in
hibi
tion
![Page 21: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/21.jpg)
IC50 of morphine in Intact MVD after incubation with 1 IC50 for 2 hr (n = 6-8)
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
110%
0.E+00 1.E-09 3.E-09 1.E-08 3.E-08 1.E-07 3.E-07 1.E-06 3.E-06
Molarity of drug
pert
cent
of
inhi
biti
on
![Page 22: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/22.jpg)
IC50 of morphine in Intact MVD after incubation with 2 IC50 for 4 hr (n = 6-8)
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
110%
0.E+00 1.E-09 3.E-09 1.E-08 3.E-08 1.E-07 3.E-07 1.E-06 3.E-06
Molarity of drug
perc
ent
of in
hibi
tion
![Page 23: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/23.jpg)
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
110%
0.E+00 1.E-09 3.E-09 1.E-08 3.E-08 1.E-07 3.E-07 1.E-06 3.E-06
Molarity of drug
perc
ent o
f inh
ibiti
onIC50 of morphine in Intact MVD after incubation
with 4 IC50 for 2 hr (n = 6-8)
![Page 24: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/24.jpg)
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
110%
0.E+00 1.E-09 3.E-09 1.E-08 3.E-08 1.E-07 3.E-07 1.E-06 3.E-06 1.E-05
Molarity of drug
perc
ent o
f inh
ibiti
onIC50 of morphine in cholestatic MVD 4 days after
cholestasis (n = 6-8)
![Page 25: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/25.jpg)
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
110%
0.E+00 1.E-09 3.E-09 1.E-08 3.E-08 1.E-07 3.E-07 1.E-06 3.E-06 1.E-05
Molarity of drug
perc
ent o
f inh
ibiti
onIC50 of morphine in cholestatic MVD 5 days after
cholestasis (n = 6-8)
![Page 26: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/26.jpg)
Degree of tolerance in MVDs incubated with different IC50s of morphine
Degree of tolerance
IC50 (molar)Animal or tissue
2.7164.40 E- 075 days Cholestasis
4.9908.09 E- 074 days Cholestasis
0.2173.52 E- 08Intact, 4 IC50-2hr
1.3242.15 E- 07Intact, 2 IC50-4hr
1.6052.60 E- 07Intact, 2 IC50-2hr
1.7652.86 E- 07Intact, 1 IC50-2hr
11.62 E- 07Intact, 0.5 IC50-2hr
11.62 E- 07Intact, No incubation
![Page 27: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/27.jpg)
Degree of tolerance in MVDs incubated with ACEA
Degree of toleranceIC50 (molar)Animal or tissue
1.6791.78E-075 day Cholestasis
1.3841.47E-07Intact-2 IC50-4hr
11.06E-07Intact
![Page 28: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/28.jpg)
Degree of tolerance in GPIs incubated with different IC50s of morphine
Degree of tolerance
IC50 (molar)Animal or tissue
0.551.59E-085 day Cholestasis
0.922.66E-08Intact-4 IC50-2hr
1.724.99E-08Intact-2 IC50-2hr
1.002.90E-08Intact
![Page 29: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/29.jpg)
Results(for dependency)
![Page 30: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/30.jpg)
• In intact MVDs which have been incubated with 2 and 4 IC50 of morphine for 2 hr, naloxone (10-5 and 10-3 molar) neither elicits any contraction nor it augments contractions caused by electrical stimulation
• The above mentioned issue holds true in 4 and 5 days cholestatic MVDs
![Page 31: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/31.jpg)
Discussion & conclusion
![Page 32: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/32.jpg)
It appears that morphine has behaved unexpectedly!!!
Why?
??
??
?
??
? ? ?
?
??
![Page 33: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/33.jpg)
It appears that morphine has behaved unexpectedly!!!
Why?
No body exactly knows !!!
![Page 34: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/34.jpg)
We know that: 1
• Opioid agonists such as morphine have been found to exert excitatory and inhibitory receptor-mediated effects at low and high doses, respectively (powell et al J Pharmacol Exp Ther. 2002)
• morphine exerted biphasic effects on clonic seizure threshold with anticonvulsant effect at lower and proconvulsant effect at a higher doses (Dehpour et al. Neuropharmacology. 2004)
![Page 35: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/35.jpg)
• Systemic administration of ultra-low doses of naltrexone potentiated the anticonvulsant effect of morphine (Dehpour et al, Neuroscience. 2004)
• Significant potentiation of analgesic effects of opioids can be achieved by ultra-low doses of opioid receptor antagonists (Dehpour et al, Neuroscience. 2004)
We know that: 2
![Page 36: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/36.jpg)
We know that: 3
• alpha2-Adrenoceptors play a dual role in the anticonvulsant effects of morphine. (Dehpour et al, Epilepsia. 2002)
• Ultra-low doses of opioid antagonists which inhibit the excitatory effects, inhibit the development of tolerance/physical dependence (powell et al J Pharmacol Exp Ther. 2002)
![Page 37: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/37.jpg)
We know that: 4
• Large doses of spinal morphine have produced a distinctive paradoxical algesic response (Michael et al, Biopolymers. 2005)
• The paradoxical effects of opioid antagonists on pain sensitivity are thought to result from a bimodal G protein-coupled µ-opioid receptor. Its activity produces excitatory effects in response to ultra-low doses of agonist and inhibitory effects in response to high doses (Crain and Shen, 1995 , 1998)
![Page 38: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/38.jpg)
• Systemic injection of heroin or morphine produced a rebound hyperalgesia after the antinociceptive effect was terminated (Michael et al, Biopolymers. 2005)
• many patients developed hyperesthesia and allodynia after continuous morphine administration (Michael et al, Biopolymers. 2005)
We know that: 5
![Page 39: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/39.jpg)
conclusion
Morphine (and cannabinoids?) does not always behave as we guess !!!
![Page 40: Cross tolerance & cross dependency](https://reader033.vdocuments.net/reader033/viewer/2022061219/54b899554a7959ce398b457b/html5/thumbnails/40.jpg)